WO2007059116A3 - Derives de geldanamycine et compositions pharmaceutiques associees - Google Patents

Derives de geldanamycine et compositions pharmaceutiques associees Download PDF

Info

Publication number
WO2007059116A3
WO2007059116A3 PCT/US2006/044165 US2006044165W WO2007059116A3 WO 2007059116 A3 WO2007059116 A3 WO 2007059116A3 US 2006044165 W US2006044165 W US 2006044165W WO 2007059116 A3 WO2007059116 A3 WO 2007059116A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
geldanamycin derivatives
derivatives
methods
geldanamycin
Prior art date
Application number
PCT/US2006/044165
Other languages
English (en)
Other versions
WO2007059116A2 (fr
Inventor
Chunlin Tao
Hongna Han
Xiaowen Sun
Tapas De
Neil P Desai
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience Inc
Chunlin Tao
Hongna Han
Xiaowen Sun
Tapas De
Neil P Desai
Patrick Soon-Shiong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Inc, Chunlin Tao, Hongna Han, Xiaowen Sun, Tapas De, Neil P Desai, Patrick Soon-Shiong filed Critical Abraxis Bioscience Inc
Publication of WO2007059116A2 publication Critical patent/WO2007059116A2/fr
Publication of WO2007059116A3 publication Critical patent/WO2007059116A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés de geldanamycine et des méthodes de production de ceux-ci. L'invention concerne également des méthodes de traitement d'une maladie ou d'un état pathologique associés à une prolifération cellulaire indésirable à l'aide desdits dérivés.
PCT/US2006/044165 2005-11-14 2006-11-14 Derives de geldanamycine et compositions pharmaceutiques associees WO2007059116A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73656305P 2005-11-14 2005-11-14
US60/736,563 2005-11-14

Publications (2)

Publication Number Publication Date
WO2007059116A2 WO2007059116A2 (fr) 2007-05-24
WO2007059116A3 true WO2007059116A3 (fr) 2007-07-26

Family

ID=37983582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/044165 WO2007059116A2 (fr) 2005-11-14 2006-11-14 Derives de geldanamycine et compositions pharmaceutiques associees

Country Status (1)

Country Link
WO (1) WO2007059116A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034375B2 (en) 2005-02-18 2011-10-11 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US9399071B2 (en) 2010-06-04 2016-07-26 Abraxis Bioscience, Llc Methods of treatment of pancreatic cancer

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
DE102006026464A1 (de) * 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
DE102006044472A1 (de) * 2006-09-21 2008-04-03 Discovery Partner International Gmbh Geldanamycin-Derivate
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN102115460B (zh) * 2010-01-05 2014-08-20 杭州华东医药集团生物工程研究所有限公司 格尔德霉素衍生物及其制备方法和用途
CN107158389A (zh) 2010-03-29 2017-09-15 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
SG10201906075VA (en) 2010-03-29 2019-08-27 Abraxis Bioscience Llc Methods of treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079167A1 (fr) * 2001-03-30 2002-10-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derive de geldanamycine et procede de traitement du cancer a l'aide de celui-ci
US6855705B1 (en) * 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
WO2005056531A1 (fr) * 2003-11-12 2005-06-23 Kosan Biosciences, Inc. Composes 11-o-methylgeldanamycine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079167A1 (fr) * 2001-03-30 2002-10-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derive de geldanamycine et procede de traitement du cancer a l'aide de celui-ci
US6855705B1 (en) * 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
WO2005056531A1 (fr) * 2003-11-12 2005-06-23 Kosan Biosciences, Inc. Composes 11-o-methylgeldanamycine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SCHNUR ET AL: "erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, 1995, pages 3813 - 3820, XP002193280, ISSN: 0022-2623 *
SCHNUR ET AL: "Inhibition of the Oncogene Product p185erb-b2 in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 19, 1995, pages 3806 - 3812, XP002202371, ISSN: 0022-2623 *
TIAN Z-Q ET AL: "Synthesis and biological activities of novel 17-aminogeldanamycin derivatives", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 12, no. 20, 15 October 2004 (2004-10-15), pages 5317 - 5329, XP004573353, ISSN: 0968-0896 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034375B2 (en) 2005-02-18 2011-10-11 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US9399071B2 (en) 2010-06-04 2016-07-26 Abraxis Bioscience, Llc Methods of treatment of pancreatic cancer

Also Published As

Publication number Publication date
WO2007059116A2 (fr) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007059116A3 (fr) Derives de geldanamycine et compositions pharmaceutiques associees
WO2006124713A3 (fr) 4-biarylyl-1-phenylazetidin-2-ones
WO2006023627A8 (fr) Polymorphes de rapamycine et leurs utilisations
WO2008034013A3 (fr) Dispositifs médicaux et procédés de réalisation desdits dispositifs
WO2008121767A3 (fr) Polypeptides cousus
WO2006124748A3 (fr) Composes polycycliques et procedes pour les utiliser
WO2007076423A3 (fr) INHIBITEURS D’ACTIVITE Akt
TW200720085A (en) Multilayer articles having acoustical absorbance properties and methods of making and using the same
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2006058201A3 (fr) Composes heterocycliques et bicycliques, compositions et procedes
WO2008115469A3 (fr) Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
AU2005339139A8 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2006127757A3 (fr) Fusion interferon-igg
WO2007137071A3 (fr) Compositions de r(+) et s(-) pramipéxole et procédés d'utilisation de celles-ci
WO2006100082A3 (fr) Derives d'oxindole substitues, medicaments contenant ces derives et leur utilisation
WO2007059008A3 (fr) Indenoisoquinolines n-substituees et leur synthese
WO2007075870A3 (fr) Procedes pour derives de taxane et intermediaires utiles correspondants
WO2007059341A3 (fr) Modulateurs de la proteine kinase a base de pyrazolothiazole
WO2008060795A3 (fr) Articles antimicrobiens et procédé de fabrication
HK1110025A1 (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives the treatment of infertility
WO2006091836A8 (fr) Preparations de tartrate de ladostigil
EP1867623A4 (fr) Dérivés de terphénylène, dérivés de tétrahaloterphényle et procédés pour la production de ceux-ci
WO2007006591A3 (fr) Dihalogenation d'hydroxipyridones n,o-disubstituees et leurs utilisations
WO2006078998A3 (fr) Methodes et compositions permettant de reduire la production de salive

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837547

Country of ref document: EP

Kind code of ref document: A2